Today: 3 March 2026
Subscribe
Browse Category

Stock Market 8 October 2025

Adaptimmune Therapeutics (ADAP) Stock Skyrockets 42% – Is This Biotech Turnaround for Real?

Adaptimmune Therapeutics (ADAP) Stock Skyrockets 42% – Is This Biotech Turnaround for Real?

Adaptimmune Therapeutics shares soared 42% to around $0.20 on Oct. 8, 2025, after weeks of extreme volatility and trading volumes topping 705 million shares. The company sold its four main cell therapy programs, including newly approved Tecelra, for $55 million upfront in July to pay off debt and cut its workforce by 62%. Weiss Ratings issued a rare “Sell (E+)” on Oct. 8. No new products have been announced this month.
8 October 2025
·
CrowdStrike Stock Skyrockets Amid Cybersecurity Boom – Is the Rally Justified? (2025 Update)

CrowdStrike Stock Skyrockets Amid Cybersecurity Boom – Is the Rally Justified? (2025 Update)

CrowdStrike shares trade near $500 after a 65% year-on-year surge, giving the cybersecurity firm a $125 billion market cap and a valuation of about 135 times forward earnings. The company agreed in August to buy Onum for $290 million and unveiled new AI-powered security features in September. Revenue rose 21% last quarter to $740 million with EPS of $0.93. Wall Street remains broadly bullish, with most analysts rating the stock a Buy.
8 October 2025
···
Moderna, Inc. (MRNA) Stock Update – Oct 8 2025: Will the mRNA Trailblazer Bounce Back or Sink Further?

Moderna, Inc. (MRNA) Stock Update – Oct 8 2025: Will the mRNA Trailblazer Bounce Back or Sink Further?

Moderna closed at $27.34 on Oct 7, 2025, with a market cap near $11 billion. Q2 revenue fell 41% year-over-year to $142 million, and the company posted a net loss of $0.8 billion. U.S. and EU regulators limited updated COVID booster use, narrowing near-term revenue prospects. Analysts’ 12-month price targets remain high, but sales forecasts have repeatedly missed expectations.
8 October 2025
··
Intellia Therapeutics (NTLA) Soars on CRISPR Breakthroughs – Latest Updates & Stock Outlook

Intellia Therapeutics (NTLA) Soars on CRISPR Breakthroughs – Latest Updates & Stock Outlook

Intellia’s NTLA-2001 gene editing therapy cut TTR protein by about 90% for three years in transthyretin amyloidosis patients, with improved outcomes and no new safety issues, according to data presented Sept. 25 and published in NEJM. Enrollment finished for the Phase 3 HAELO trial of NTLA-2002, with top-line results expected in 1H 2026. Intellia stock is up over 60% in 2025. Q2 revenue more than doubled to $14.25 million.
8 October 2025
···
TSMC Stock Soars on AI Boom: Record Highs, Big Ambitions & Geopolitical Risks (Oct 2025 Update)

TSMC Stock Soars on AI Boom: Record Highs, Big Ambitions & Geopolitical Risks (Oct 2025 Update)

TSMC shares hover near record highs, up about 45% in 2024, as Q2 revenue surged 44% year-on-year to $30.1 billion on AI chip demand. Morgan Stanley and Bank of America raised targets ahead of Q3 results due Oct. 16. Taiwan rejected U.S. calls to split chip output, while Chinese drills raised energy security concerns. TSMC aims to start 2nm chip mass production by late 2025.
8 October 2025
··
Cisco’s $2B AI Windfall: New Tech, Stock Surge & What’s Next for CSCO

Cisco’s $2B AI Windfall: New Tech, Stock Surge & What’s Next for CSCO

Cisco unveiled a 51.2 Tbps router and Silicon One P200 chip for AI data centers on Oct. 8, 2025, with Microsoft and Alibaba as initial buyers. Fiscal 2025 revenue reached $56.7 billion, up 5%, and AI-focused orders topped $2 billion. Shares trade near $69 with a 2.4% dividend yield. Wall Street rates the stock a “Moderate Buy,” with an average 12-month price target of $74–75.
8 October 2025
··
UnitedHealth Group Stock Surges Amid Analyst Upgrades: Is Wall Street Turning Bullish on UNH in 2025?

UnitedHealth Group Stock Surges Amid Analyst Upgrades: Is Wall Street Turning Bullish on UNH in 2025?

UnitedHealth Group closed near $372 on Oct. 8, up over 2%, but remains far below its April high of $630. The company reported $422.8 billion in trailing 12-month revenue and $21.3 billion net income. Analysts raised price targets after recent upgrades, but the stock faces pressure from rising medical costs and regulatory probes. Third-quarter results are due Oct. 28, with guidance cut to $14.65 per share.
8 October 2025
·
Palo Alto Networks’ AI-Fueled Surge: Stock Soars on Cybersecurity Boom, Bold Forecasts & Big Deals

Palo Alto Networks’ AI-Fueled Surge: Stock Soars on Cybersecurity Boom, Bold Forecasts & Big Deals

Palo Alto Networks traded near $216 on October 8, 2025, approaching multi-month highs and a $135–140 billion market cap. Unit 42 uncovered a major China-linked hacking campaign targeting foreign ministries’ emails. Fiscal Q4 revenue rose 16% to $2.5 billion, with adjusted EPS up 16% to 95¢. Wall Street maintains a strong buy rating, with price targets averaging $215–220.
8 October 2025
···
Confluent, Inc. (CFLT) – Will a Real‑Time Data Pioneer Become a Takeover Target? (October 8 2025)

Unraveling Confluent (CFLT) Stock: Latest Price, AI‑Driven Buzz & What Experts Say

Confluent closed at $22.84 on Oct. 8, down 10% after Reuters reported the company is exploring a sale following interest from private-equity and tech firms. The stock surged 20% pre-market on the news and remains volatile. Q2 results showed 21% subscription revenue growth, but management warned of slower cloud consumption. Market cap stands near $7.3 billion, with a 52-week range of $15.64 to $37.90.
8 October 2025
··
AI Drug Discovery Darling? Recursion Pharma (RXRX) Stock’s Wild Ride in 2025

AI Drug Discovery Darling? Recursion Pharma (RXRX) Stock’s Wild Ride in 2025

Recursion Pharmaceuticals’ stock jumped 16% to $6.08 on October 8, 2025, after falling over 5% the previous day. The company uses AI to accelerate drug discovery and recently reported Q2 revenue of $19.2 million, up 33% year-over-year, but posted a net loss of $171.9 million. Recursion holds about $534 million in cash. Recent moves include acquiring Exscientia and cutting several pipeline programs.
8 October 2025
···
AiRWA (YYAI) Stock Soars 44% on $100M Crypto Pivot – Expert Insights

AiRWA (YYAI) Stock Soars 44% on $100M Crypto Pivot – Expert Insights

AiRWA Inc. (Nasdaq: YYAI), formerly Connexa Sports, rebranded and shifted to blockchain, securing a $100 million commitment from JuCoin Capital and receiving $30 million in Solana tokens. Shares jumped 32% to $0.2375 on Oct. 8 after plunging 92.8% the prior day. Market cap stands at $3.8 million with high short interest. The company faces SEC warnings over continued operations despite reporting FY2025 revenue of $12.8 million.
8 October 2025
··
Webull’s Wild Ride: Inside BULL Stock’s 500% Surge, 85% Crash & What’s Next for the Trading App Giant

Webull’s Wild Ride: Inside BULL Stock’s 500% Surge, 85% Crash & What’s Next for the Trading App Giant

Webull (NASDAQ: BULL) surged nearly 500% to $79.56 after its April 2025 SPAC debut, then plunged over 85%; shares traded near $12 on Oct. 8, just above their 52-week low. A lock-up expiration in October released 455.6 million insider shares, triggering a two-day selloff. Q2 revenue rose 46% to $131.5 million, but the company remains unprofitable on a net basis. Analysts set price targets near $18.50, citing strong growth.
8 October 2025
·
Quantum Gold Rush: Inside D-Wave (QBTS) Stock’s 2600% Surge – Hype or Game-Changer?

Quantum Gold Rush: Inside D-Wave (QBTS) Stock’s 2600% Surge – Hype or Game-Changer?

D-Wave Quantum shares soared to all-time highs near $33 in early October 2025, up over 3,000% from a year ago, pushing its market cap to $10–11 billion—about 400 times annual revenue. Q2 revenue reached $3.1 million while net loss hit $167 million. Technical breakthroughs and partnerships fueled the rally, but analysts warn the surge may be unsustainable. Trading remains volatile, with record volumes and heavy options activity.
8 October 2025
···
QuantumScape’s EV Battery Breakthrough Sends Stock Soaring – Will the High-Voltage Hype Last?

QuantumScape’s EV Battery Breakthrough Sends Stock Soaring – Will the High-Voltage Hype Last?

QuantumScape shares soared 170% in 2025, closing at $15.92 on Oct. 3 after an 11% daily gain, following a partnership with Corning and a Ducati prototype demo using its battery cells. The company expanded its deal with Murata on Oct. 8 to speed up mass production. Despite the surge, most analysts rate QS a “Sell” or “Reduce,” citing no product revenue and a $9 billion market cap.
8 October 2025
···
Joby Aviation’s $500 Million Stock Gamble Triggers Selloff – Can the Air Taxi Dream Still Soar?

Joby Aviation’s $500 Million Stock Gamble Triggers Selloff – Can the Air Taxi Dream Still Soar?

Joby Aviation shares fell about 9% after the company announced a $500 million public stock offering at $16.85 per share, with an additional $75 million option for underwriters. The move will dilute existing shareholders by roughly 15–20%. Joby plans to use the funds for FAA certification and ramping up electric air taxi production. Shares opened Oct. 8 down from the prior close, trading near $17.24 after hours.
8 October 2025
·
Wall Street’s $2 Billion Bet on the Future: NYSE Owner Goes All-In on Polymarket Prediction Markets

Wall Street’s $2 Billion Bet on the Future: NYSE Owner Goes All-In on Polymarket Prediction Markets

Intercontinental Exchange, owner of the NYSE, is investing up to $2 billion in Polymarket, valuing the crypto-based prediction market platform at $8–10 billion. ICE’s stock rose about 4% after the announcement before stabilizing. Polymarket recently secured U.S. regulatory approval after acquiring a CFTC-licensed exchange. The U.S. launch is pending final regulatory steps.
8 October 2025
···
Rocket Lab Soars to New Heights After Mega Launch Deal – What’s Next for the Space Stock?

Rocket Lab Soars to New Heights After Mega Launch Deal – What’s Next for the Space Stock?

Rocket Lab shares hit an all-time high near $66 in early October after announcing a new multi-launch contract with Japan’s iQPS. The stock is up nearly 700% from a year ago. Rocket Lab is on pace for over 20 launches in 2025 and holds a backlog approaching $1 billion. Despite record revenue, the company remains unprofitable, posting a $66 million net loss in Q2.
8 October 2025
···
Verizon Goes to Space: AST SpaceMobile Deal Signals End of Dead Zones – Stock Rockets on Breakthroughs

Verizon Goes to Space: AST SpaceMobile Deal Signals End of Dead Zones – Stock Rockets on Breakthroughs

Verizon and AST SpaceMobile signed a commercial deal to launch direct-to-phone satellite broadband across the U.S. starting in 2026. Recent tests connected standard 4G phones via AST’s satellite between Texas and New Jersey. AST’s stock surged over 200% in 2025, hitting record highs after the announcement. More than 50 global carriers have partnered with AST to offer similar services.
8 October 2025
·····
1 … 1,281 1,282 1,283 1,284 1,285 … 1,323
Go toTop